The CMS will now cover diagnostic laboratory tests using gene sequencing technology for Medicare cancer patients. The agency said the tests can help patients and their oncologists make better treatment decisions.
Cancer specialists are urging physicians and patients to consider testing for gene mutations tied to prostate cancer, though questions linger about its cost-effectiveness.
A new study published in JAMA Surgery finds that addressing racial health disparities requires better cultural competency among medical researchers as well as healthcare providers.
The U.S. Preventive Services Task Force is discouraging ovarian cancer screening for asymptomatic women, saying it's ineffective and has a high incidence of false-positives and doesn't curb mortality rates.
UCLA Health rethought its approach to how it sends patients FIT kits, an at-home test patients can take to screen for colon cancer.
First Descents' mission is to provide outdoor experiences free for 18- to 39-year olds diagnosed with cancer. The weeklong and multiday adventure experiences include activities like whitewater kayaking, rock climbing and surfing.
Tempus, Eric Lefkofsky's startup that's tackling cancer treatment with big data, just got a major boost in the data department. The Chicago-based company and a partner are getting access to CancerLinQ, a database of treatment results developed by the American Society of Clinical Oncology.
Claims data can be a resource for identifying patients with unusual care needs.
Oncologists often feel pressure from breast cancer patients to provide longer and more costly treatments even when the patient is eligible for less aggressive options, a new study revealed.
With more people surviving cancer, programs to help them stay healthy after treatment are growing, but are still concentrated at large, expensive academic centers.
Tempus, Eric Lefkofsky's cancer-data company, is getting a $70 million boost from some familiar partners: New Enterprise Associates and Revolution Growth. The two Washington, D.C.-area venture funds led a new round of financing that brings the total outside investments in Tempus to $130 million.
The cancer community is deploying advanced-practice providers to help address a shortage of services. But integrating them into a practice isn't easy.